Korean Precision Medicine Project KOSMOS Receives $1.5 Billion Investment from Roche to Provide Integrated Solutions from Diagnosis to Treatment
Korean precision medicine project KOSMOS has received a huge investment of 170 billion won from the South Korean biotech company, Roche. Even global pharmaceutical companies like Roche are investing heavily in precision medicine in Korea. Professors from the Korean Society of Medical Oncology and the Korean Association for Cancer Research have been supporting the development of Korea's precision medicine. Roche is creating a customized medical ecosystem at a global level, aiming to provide a comprehensive solution for cancer patients, from diagnosis to treatment. The company is the first to participate in a partnership and has committed to providing necessary medication and diagnostic solutions for the research. Roche's aim is to lower the increasing social and economic burden while accelerating new drug development in academia and industry. By partnering with the world's top diagnostics company and the top biopharmaceutical company, Roche can provide an integrated solution throughout the entire process from diagnosis to treatment and monitoring.
Starting from 2020 and for the next five years, Roche will provide 170 billion won worth of medication, examination, and platform services for KOSMOS 1 and 2 research. Roche is playing a significant role in KOSMOS research, which begins with a patient's next-generation sequencing (NGS) test. NGS test results are stored in a tumor board, where multiple specialists can review and discuss them together. Roche Diagnostics provides genome testing services, and its Molecular Tumor Board (MTB) called "Navify Tumor Board" is also available in this process.
In particular, Navify Tumor Board is a tumor board specialized in cancer treatment, collecting and compiling patient data required in multi-disciplinary treatment, such as tissue examinations and imaging information, onto a single dashboard. It also helps identify similar cases of patients quickly.
Different medical professionals from different hospitals come together for multi-disciplinary treatment, so the decision-making process can take a long time. Navify provides various information to enable prompt and efficient decision-making by different medical professionals. Roche's participation in KOSMOS research is a significant step toward developing a comprehensive precision medicine solution for cancer patients in Korea.